Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:31 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
NCT04383210 · Elevation Oncology · PHASE2 · terminated · last registry update 2025-04-03 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Business decision” | Open Targets' class: business administrative | Registry record, Elevation Oncology |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ERBB3 in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-02-20Also stopped (terminated): M.D. Anderson Cancer Center, Poziotinib (NCT03066206)
- 2025-12-16Results posted on the registry: Medical University of South Carolina, Sotorasib and Tarloxotinib + Sotorasib and Tarloxotinib (NCT05313009)
- 2025-12-16Also stopped (terminated): Medical University of South Carolina, Sotorasib and Tarloxotinib + Sotorasib and Tarloxotinib (NCT05313009)
- 2024-06-25Results posted on the registry: Spectrum Pharmaceuticals, Inc, Poziotinib Once Daily Dosing + Poziotinib Twice Daily Dosing (NCT04402008)
- 2024-06-25Also stopped (terminated): Spectrum Pharmaceuticals, Inc, Poziotinib Once Daily Dosing + Poziotinib Twice Daily Dosing (NCT04402008)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision